Skip to content

ChemoCentryx, Inc.

Delisted

CIK 1340652fmd_06R0EX98SMRR98019RZ6AJXTXGManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2010 to Jun 30, 2022, 47 periods

Latest annual · FY2021

Millions
Total revenues
32
Operating income
(130)
Net income
(132)
Free cash flow
(95)

Latest quarter · Q2 FY2022

Millions
Total revenues
12
Operating income
(32)
Net income
(32)
Free cash flow
(27)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2018 to FY2021
-9.1%
Revenue, 5 yearsFY2016 to FY2021
+22.0%
Net income, 5 yearsFY2016 to FY2021
n/m

ChemoCentryx, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2021FY2020ChangeSource
Revenue$32.2 million$64.9 million-50.3%10-K 2022-03-01 · proof
Operating income-$129.9 million-$55.2 million10-K 2022-03-01 · proof
Net income-$131.8 million-$55.4 million10-K 2022-03-01 · proof
Cash from operating activities-$75.6 million-$81.1 million10-K 2022-03-01 · proof
Free cash flow-$94.6 million-$96.6 million10-K 2022-03-01 · proof
Total assets$425.7 million$518.9 million-18%10-K 2022-03-01 · proof
Total liabilities$139.5 million$133.3 million+4.7%10-K 2022-03-01 · proof
Cash and cash equivalents$50 million$32.3 million+54.7%10-K 2022-03-01 · proof
Total debt$23.6 million$24.4 million-3.1%10-K 2022-03-01 · proof
What was ChemoCentryx, Inc.'s revenue in fiscal 2021?
ChemoCentryx, Inc. reported revenue of $32.2 million for fiscal 2021 (the year ended Dec 31, 2021), against $64.9 million the year before (-50.3%). Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What was ChemoCentryx, Inc.'s operating income in fiscal 2021?
ChemoCentryx, Inc. reported operating income of -$129.9 million for fiscal 2021 (the year ended Dec 31, 2021), against -$55.2 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What was ChemoCentryx, Inc.'s net income in fiscal 2021?
ChemoCentryx, Inc. reported net income of -$131.8 million for fiscal 2021 (the year ended Dec 31, 2021), against -$55.4 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What was ChemoCentryx, Inc.'s cash from operating activities in fiscal 2021?
ChemoCentryx, Inc. reported cash from operating activities of -$75.6 million for fiscal 2021 (the year ended Dec 31, 2021), against -$81.1 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What was ChemoCentryx, Inc.'s free cash flow in fiscal 2021?
ChemoCentryx, Inc. reported free cash flow of -$94.6 million for fiscal 2021 (the year ended Dec 31, 2021), against -$96.6 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What are ChemoCentryx, Inc.'s total assets?
As of Dec 31, 2021, ChemoCentryx, Inc. reported total assets of $425.7 million, against $518.9 million a year earlier (-18%). Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What are ChemoCentryx, Inc.'s total liabilities?
As of Dec 31, 2021, ChemoCentryx, Inc. reported total liabilities of $139.5 million, against $133.3 million a year earlier (+4.7%). Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What are ChemoCentryx, Inc.'s cash and cash equivalents?
As of Dec 31, 2021, ChemoCentryx, Inc. reported cash and cash equivalents of $50 million, against $32.3 million a year earlier (+54.7%). Source: the 10-K filed with the SEC on Mar 1, 2022. SEC
What is ChemoCentryx, Inc.'s total debt?
As of Dec 31, 2021, ChemoCentryx, Inc. reported total debt of $23.6 million, against $24.4 million a year earlier (-3.1%). Source: the 10-K filed with the SEC on Mar 1, 2022. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1340652&period_type=annual&limit=5"

Information only, not investment advice.